The Daiichi Sankyo Group is one of the world's 20 leading global pharmaceutical companies. By 2015, the company wants to achieve recognition as a "Global Pharma Innovator".
In this context "Global" means that the group wants to continue its expansion into other markets in the world, where it is not yet represented with own affiliates or subsidiaries. "Pharma" means Daiichi Sankyo's constant, unceasing and passionate efforts to fulfill unmet medical needs of patients in both mature and emerging markets. "Innovator" describes the efforts to be an innovative company in science, technology and with regard to group's business model.
Quantified into figures, this means we intend to achieve the following by 2015:
Net sales of €12.5 billion (¥1,500 billion)
Operating income margin of 25 per cent or more
Overseas sales ratio of 60 per cent or more